Monitor upcoming launch of PURE Clean in Q3 and its impact on revenue trajectory. Watch for signs of cash burn stabilization and whether revenue growth can accelerate to offset high fixed costs. The significant related-party debt warrants attention regarding future dilution or refinancing risk.
Price Chart
Executive Summary
PURE Bioscience reported fiscal Q2 2026 financial results with net product sales increasing 13.3% year-over-year to $443,000 and net loss narrowing slightly to $785,000 from $798,000. The company highlighted progress including USDA Biobased Product Certification for its new PURE Clean product, expected to launch in Q3, and ongoing expansion in dairy, transportation, and biomedical markets.
Key Financial Metrics
Key Facts
- Net product sales were $443,000 in Q2 FY2026, up from $391,000 in Q2 FY2025 (13.3% YoY growth)
- Net loss was $785,000 in Q2 FY2026 vs. $798,000 in Q2 FY2025
- Net loss per share remained flat at ($0.01)
- Received USDA Biobased Product Certification for new product PURE Clean, with official launch expected in Q3
- Cash and cash equivalents decreased to $198,000 from $334,000 at prior year-end
- Convertible notes payable to related parties increased significantly to $6.145 million total ($2.139 million current, $4.006 million non-current)
Financial Impact
Revenue increased by $52,000 YoY while net loss decreased by $13,000. Cash balance declined by $136,000 from prior year-end despite reduced operating loss, indicating cash burn continues. Total liabilities increased significantly due to convertible notes.
Risk Factors
- Continuing net losses and negative cash flow
- High concentration of debt held by related parties
- Limited cash reserves of $198,000 against substantial liabilities
- Execution risk in launching and scaling new products
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-010383 |
| Document: form8-k.htm | 0001493152-26-010383 |
| Document: 0001493152-26-010383-index-headers.html | 0001493152-26-010383 |
| Document: 0001493152-26-010383-index.html | 0001493152-26-010383 |
| Document: 0001493152-26-010383.txt | 0001493152-26-010383 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 8-K | $0.0800 $0.0800 | · 0.00% | ▼ −1.18% | $0.0870 (−8.75%) |
Jun 15, 2026 19w ago | 8-K | $0.0600 $0.0800 | ▲ +33.33% | ▲ +34.58% | $0.0870 (+45.00%) |
May 5, 2026 25w ago | 8-K | $0.0700 $0.0700 | · 0.00% | ▼ −0.33% | $0.0870 (−24.29%) |
Mar 17, 2026 32w ago | 8-K | $0.0800 $0.0800 | · 0.00% | ▲ +1.40% | $0.0870 (+8.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers